Peripheral immune cells (PBMCs)

Peripheral immune cells encompass the diverse array of leukocytes circulating within the blood and lymphatic systems, including T cells, B cells, natural killer (NK) cells, and myeloid cells (NIH, 2023). These cells serve as the primary mediators of systemic immunity, facilitating pathogen recognition, antigen presentation, and the execution of targeted immune responses (StatPearls, 2023). In clinical medicine, these cells are frequently targeted to treat autoimmune diseases, where they are overactive, or in oncology, where their activity is often suppressed by the tumor microenvironment (Nature Reviews Immunology, 2021). Therapeutic strategies include the use of monoclonal antibodies to deplete specific subsets, small molecules to inhibit signaling pathways, and checkpoint inhibitors to enhance anti-tumor activity (PubMed, 2022). Because "Peripheral immune cells" refers to a broad cellular compartment rather than a specific molecular entity like a receptor or enzyme, it is categorized as a physiological system or therapeutic site rather than a discrete drug target (NCBI, 2023).

Other names

Peripheral blood mononuclear cellsPBMCsCirculating leukocytesSystemic immune cellsWhite blood cells

Pharmacological agents modulate peripheral immune cells by inhibiting intracellular signaling (e.g., JAK/STAT or calcineurin pathways), depleting specific cell lineages via antibody-dependent cellular cytotoxicity (ADCC), or blocking inhibitory checkpoints to restore effector function (PubMed, 2022).